BARD1 (ASX:BD1) appoints world-leading medical researcher as CSO
BARD1 Life Sciences (BD1) appoints Greg Rice as chief scientific officer (CSO)…
Bard1 Life Sciences Limited (BD1:ASX)
$1.06
-0.03 (-2.75%)
MCAP $100.2M
Last trade
15.57pm 19/10/2021
20mins delayed
Latest Announcements
11/10/2021BD1Bard1 Life Sciences Limited
01/10/2021BD1Bard1 Life Sciences Limited
29/09/2021BD1Bard1 Life Sciences Limited
3,903
MCap
16/09/2021 Price SensitivePSBD1Bard1 Life Sciences Limited
2,730
MCap
07/09/2021BD1Bard1 Life Sciences Limited
31/08/2021 Price SensitivePSBD1Bard1 Life Sciences Limited
1,562
MCap
27/08/2021BD1Bard1 Life Sciences Limited
1,102
MCap
27/08/2021BD1Bard1 Life Sciences Limited
Company Overview
BARD1 Life Sciences Limited is an Australia-based medical diagnostics company. The Company is engaged in research, development, and commercialization of non-invasive diagnostic products for the early detection of cancer. The Company’s technologies include BARD1, SubB2, NET and hTERT. BARD1 is a biomarker platform covering various tumor markers including nucleic acids, proteins, and autoantibodies for early cancer diagnosis.SubB2M is a pan-cancer probe for monitoring cancer treatment response and recurrence across a wide range of cancers. NET is designed to capture and purify biomarkers, including acids, cells, and exosomes. hTERT is an antibody-based assay to detect hTERT, a component of telomerase, in cells.
